3326-31-6 Usage
Description
3',6'-Dihydroxy-6-isothiocyanatospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one is a complex organic compound characterized by its unique molecular structure. It is a derivative of spiro compounds, which are composed of two rings fused together in a spiro arrangement. The presence of hydroxy and isothiocyanato functional groups in its structure endows it with specific chemical properties and potential applications in various fields.
Uses
Used in Pharmaceutical Industry:
3',6'-Dihydroxy-6-isothiocyanatospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one is used as a pharmaceutical compound for its potential therapeutic applications. The hydroxy and isothiocyanato groups in its structure may allow for interactions with biological targets, making it a candidate for the development of new drugs.
Used in Fluorescence Polarization Binding Assays:
In the field of biochemistry and molecular biology, 3',6'-Dihydroxy-6-isothiocyanatospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one is used as a fluorescent reagent. It is particularly useful in fluorescence polarization binding assays, where it can be employed to develop inhibitors of specific protein targets, such as the inactive p38α Mitogen-activated protein kinase (MAPK). 3',6'-Dihydroxy-6-isothiocyanatospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one's fluorescence properties enable the monitoring of binding events and the assessment of compound efficacy in inhibiting the target protein.
Used in Drug Delivery Systems:
Similar to gallotannin, 3',6'-Dihydroxy-6-isothiocyanatospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one may also be utilized in the development of drug delivery systems. Its unique structure and functional groups could be exploited to improve the delivery, bioavailability, and therapeutic outcomes of various drugs, particularly in the context of cancer treatment. Organic and metallic nanoparticles could be employed as carriers for this compound, enhancing its potential applications in the pharmaceutical industry.
Check Digit Verification of cas no
The CAS Registry Mumber 3326-31-6 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 3,3,2 and 6 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 3326-31:
(6*3)+(5*3)+(4*2)+(3*6)+(2*3)+(1*1)=66
66 % 10 = 6
So 3326-31-6 is a valid CAS Registry Number.
InChI:InChI=1/C21H11NO5S/c23-12-2-5-15-18(8-12)26-19-9-13(24)3-6-16(19)21(15)17-7-11(22-10-28)1-4-14(17)20(25)27-21/h1-9,23-24H
3326-31-6Relevant articles and documents
Nucleic acid size detection method
-
, (2012/05/04)
The present invention provides methods of determining the size of a particular nucleic acid segment of interest in a sample of nucleic acids through fragmentation of DNA, size fractionation, an optional second fragmentation, and identification using a marker sequence. In particular aspects, an expansion or reduction of tandem repeat sequences can be detected. In further aspects, carriers and individuals afflicted with fragile X syndrome or other diseases associated with tandem repeats can be distinguished from normal individuals.
PHARMACEUTICAL COMPOSITION CONTAINING STATIN-ENCAPSULATED NANOPARTICLE
-
, (2009/06/27)
The present invention provides a novel nanotechnology-based strategy for therapeutic neovascularization. Said statin-loaded nanoparticle allows local delivery of statin and thus improves therapeutic efficacy of several kind of diseases which may treated by statin such as ischemic neovascularization.
Activatable probes and methods for in vivo gene detection
-
, (2008/06/13)
Probes for detecting a target polynucleotide are provided. One aspect provides a molecular beacon probe set wherein the donor molecular beacon comprises a quantum dot and an acceptor molecular beacon comprises at least one reporter. The probes optionally comprise a protein transduction domain, targeting signal, or a combination thereof. Methods for detecting target polynucleotides using the disclosed probes are also provided.